On Behalf of the ALLG

Australasian Leukaemia and Lymphoma Group
Melbourne Australia Papers:
459 Combination of Nilotinib and Pegylated Interferon Alfa-2b Results in High Molecular Response Rates in Chronic Phase CML: Interim Results of the ALLG CML 11 Pinnacle Study